Cagrilintide is a long-acting amylin receptor agonist studied for its appetite-suppressing and gastric-emptying delaying effects. In metabolic research models, it has been evaluated in combination with GLP-1 receptor agonists such as Semaglutide and Tirzepatide for enhanced weight loss and improved metabolic outcomes. Cagrilintide acts on the hypothalamus to regulate satiety signals, making it a promising target for multi-hormonal obesity therapy.
Purity:
≥99% (HPLC Verified)
Format:
Lyophilized powder
Storage:
Store at -20°C, protect from light and moisture
Solvent:
Bacteriostatic Water
Concentration:
Add 1mL BAC water = 5mg/mL solution
Stability:
Store reconstituted vial at 2°C–8°C and use within 30 days
Dose:
600mcg = 0.12mL = ~12 units (using 100iu insulin syringe)
Frequency:
1x weekly; often studied in combination with GLP-1 analogs
Dosing based on 5mg/mL concentration. For laboratory reference use only.
Research Use:
Not for human or veterinary use. For educational and laboratory study only.
Qualified Use:
For licensed researchers and laboratory professionals
Scientific Basis:
Information reflects obesity, satiety, and endocrine regulation models
Reminder:
Do not misbrand, misuse, or misrepresent this compound
Diabetes Obes Metab (2022):
Disclaimer
Cagrilintide is a research compound not approved for medical use. AlphaBoost supplies this product for research and reference purposes only. It is not for human or veterinary use.
Reviews
There are no reviews yet.